Growing community of inventors

Guilford, CT, United States of America

Chris Conrad

Average Co-Inventor Count = 7.87

ph-index = 3

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 15

Chris ConradJonathan Marc Rothberg (7 patents)Chris ConradHenri Lichenstein (7 patents)Chris ConradSean Landrette (7 patents)Chris ConradPaul Beckett (7 patents)Chris ConradNeil Beeharry (7 patents)Chris ConradTian Xu (6 patents)Chris ConradSophia Gayle (6 patents)Chris ConradJonathan M Rothberg (6 patents)Chris ConradMatt Dyer (2 patents)Chris ConradMarylens Hernandez (2 patents)Chris ConradTian Xu (1 patent)Chris ConradTian Xu (0 patent)Chris ConradTian Xu (0 patent)Chris ConradChris Conrad (7 patents)Jonathan Marc RothbergJonathan Marc Rothberg (402 patents)Henri LichensteinHenri Lichenstein (31 patents)Sean LandretteSean Landrette (13 patents)Paul BeckettPaul Beckett (9 patents)Neil BeeharryNeil Beeharry (8 patents)Tian XuTian Xu (27 patents)Sophia GayleSophia Gayle (6 patents)Jonathan M RothbergJonathan M Rothberg (6 patents)Matt DyerMatt Dyer (4 patents)Marylens HernandezMarylens Hernandez (2 patents)Tian XuTian Xu (1 patent)Tian XuTian Xu (0 patent)Tian XuTian Xu (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Ai Therapeutics, Inc. (5 from 14 patents)

2. Lam Therapeutics, Inc. (2 from 2 patents)


7 patents:

1. 11266654 - Apilimod compositions and methods for using same

2. 11166944 - Apilimod compositions and methods for using same in the treatment of renal cancer

3. 10765682 - Apilimod for use in the treatment of melanoma

4. 10729694 - Anti-viral compositions containing PIKfyve inhibitors and use thereof

5. 10350213 - Methods for treating cancer using apilimod

6. 10206910 - Apilimod for use in the treatment of renal cancer

7. 10179135 - Apilimod compositions and methods for using same

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/12/2025
Loading…